FDA panel to meet and vote on whether a diabetes drug reduces the risk of cardiovascular death

Tim Casey | | Cardiovascular Business | Patient Care

An FDA panel will meet on June 28 and vote on whether empagliflozin (Jardiance) reduces the risk of cardiovascular death in high-risk patients, Reuters reports. When the FDA approved empagliflozin in 2014 to treat patients with type 2 diabetes, the agency asked the drug’s manufacturers (Eli Lilly & Co. and Boehringer Ingelheim) to conduct a trial to prove the medication did not increase the risk of heart problems.

The companies published the results in January and showed that the drug decreased the risk of death from MI, the risk of death from any cause and the combined risk of cardiac death, non-fatal MIs and non-fatal strokes.

Read the story below:

FDA panel to vote whether diabetes drug cuts cardiac death

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Related Content

Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
FDA approves Medtronic’s new all-in-one mapping and ablation system for AFib

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."